Vermeulen N P, Danhof M, Setiawan I, Breimer D D
J Pharmacol Exp Ther. 1983 Jul;226(1):201-5.
The disposition of hexobarbital was studied in rats after i.v. and i.a. administration. In addition to sleeping times, plasma concentration profiles were measured. No significant differences were found in sleeping times, volumes of distribution, elimination half-lives or systemic clearances between these different routes. The average elimination half-lives were 13.5 +/- 0.8 (n = 17) and 11.6 +/- 1.9 min (n = 21) (means +/- S.E.M.), respectively, whereas the systemic whole blood clearance values were 75.4 +/- 3.4 (n = 17) and 85.8 +/- 3.5 ml/min/kg (n = 21) (means +/- S.E.M.). The values of the latter parameter approach hepatic blood flow in the rat (i.e., 100 ml/min/kg) and therefore the oral availability of hexobarbital was established by comparing areas under plasma concentration time curves, after i.v. and oral administration to the same rat. Oral availability was found to be only 36%, which corresponds to an extraction ratio of 64%. The consequences of such a "first-pass" effect are discussed in view of the use of hexobarbital as a model substrate for measuring drug-metabolizing enzyme activity. Furthermore, it was found that anesthesia as induced by diethylether during the experiments resulted in a very significant inhibition of the rate of hepatic metabolism of hexobarbital; the elimination half-life increased by about 50% due to a similar decrease in the systemic clearance. The protein binding of hexobarbital in rat plasma amounted to 51.4 +/- 1.2% (mean +/- S.E.M., n = 15) and it was found not to be dependent on the plasma concentration of hexobarbital in the range encountered in vivo.
研究了静脉注射和腹腔注射后大鼠体内己巴比妥的处置情况。除睡眠时间外,还测量了血浆浓度曲线。这些不同给药途径在睡眠时间、分布容积、消除半衰期或全身清除率方面均未发现显著差异。平均消除半衰期分别为13.5±0.8(n = 17)和11.6±1.9分钟(n = 21)(均值±标准误),而全身全血清除率值分别为75.4±3.4(n = 17)和85.8±3.5 ml/min/kg(n = 21)(均值±标准误)。后一参数的值接近大鼠的肝血流量(即100 ml/min/kg),因此通过比较同一大鼠静脉注射和口服给药后血浆浓度-时间曲线下的面积来确定己巴比妥的口服生物利用度。发现口服生物利用度仅为36%,这对应于64%的提取率。鉴于己巴比妥作为测量药物代谢酶活性的模型底物的应用,讨论了这种“首过”效应的后果。此外,还发现实验期间由乙醚诱导的麻醉导致己巴比妥肝代谢速率受到非常显著的抑制;由于全身清除率有类似程度的降低,消除半衰期增加了约50%。己巴比妥在大鼠血浆中的蛋白结合率为51.4±1.2%(均值±标准误,n = 15),并且发现它不依赖于体内所遇到的己巴比妥血浆浓度。